Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

被引：4197

作者：

Atkinson, AJ

Colburn, WA

DeGruttola, VG

DeMets, DL

Downing, GJ

Hoth, DF

Oates, JA

Peck, CC

Schooley, RT

Spilker, BA

Woodcock, J

Zeger, SL

机构：

[1] NIH, Off Sci Policy, Bethesda, MD 20892 USA

[2] NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA

[3] MDS Harris Inc, Phoenix, AZ USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Univ Wisconsin, Dept Biostat, Madison, WI USA

[6] Axys Pharmaceut, San Francisco, CA USA

[7] Vanderbilt Univ, Dept Med, Nashville, TN USA

[8] Georgetown Univ, Ctr Drug Dev Sci, Washington, DC USA

[9] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA

[10] Pharmaceut Res & Manufacturers Amer, Washington, DC USA

[11] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA

[12] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 03期

关键词：

D O I：

10.1067/mcp.2000.113989

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：89 / 95

页数：7

共 30 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, AA
Eisen, MB
Davis, RE
Ma, C
Lossos, IS
Rosenwald, A
Boldrick, JG
Sabet, H
Tran, T
Yu, X
Powell, JI
Yang, LM
Marti, GE
Moore, T
Hudson, J
Lu, LS
Lewis, DB
Tibshirani, R
Sherlock, G
Chan, WC
Greiner, TC
Weisenburger, DD
Armitage, JO
Warnke, R
Levy, R
Wilson, W
Grever, MR
Byrd, JC
Botstein, D
Brown, PO
Staudt, LM
[J]. NATURE, 2000, 403 (6769) : 503 - 511
[2] [Anonymous], 1991, JAMA, V265, P3255
[3] Efficacy measures: Surrogates or clinical outcomes?
Blue, JW
Colburn, WA
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (09) : 767 - 770
[4] SURROGATE END-POINTS - A BASIS FOR A RATIONAL APPROACH
BOISSEL, JP
COLLET, JP
MOLEUR, P
HAUGH, M
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (03) : 235 - 244
[5] CARR G, 1998, ECONOMIST, V346, P1
[6] Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
Ciarmiello, A
Del Vecchio, S
Silvestro, P
Potena, MI
Carriero, MV
Thomas, R
Botti, G
D'Aiuto, G
Salvatore, M
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1677 - 1683
[7] Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.3.CO
[8] 2-D
[9] Importance of surrogate markers in evaluation of antiviral therapy for HIV infection
Deyton, L
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02): : 159 - 160
[10] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL
ECHT, DS
LIEBSON, PR
MITCHELL, LB
PETERS, RW
OBIASMANNO, D
BARKER, AH
ARENSBERG, D
BAKER, A
FRIEDMAN, L
GREENE, HL
HUTHER, ML
RICHARDSON, DW
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) : 781 - 788

← 1 2 3 →